{"pmid":32339335,"title":"Hematologic parameters in patients with COVID-19 infection.","text":["Hematologic parameters in patients with COVID-19 infection.","Am J Hematol","Fan, Bingwen Eugene","32339335"],"journal":"Am J Hematol","authors":["Fan, Bingwen Eugene"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339335","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ajh.25847","topics":["Treatment"],"weight":1,"_version_":1665264685495091200,"score":8.574329,"similar":[{"pmid":32129508,"title":"Hematologic parameters in patients with COVID-19 infection.","text":["Hematologic parameters in patients with COVID-19 infection.","Am J Hematol","Fan, Bingwen Eugene","Chong, Vanessa Cui Lian","Chan, Stephrene Seok Wei","Lim, Gek Hsiang","Lim, Kian Guan Eric","Tan, Guat Bee","Mucheli, Sharavan Sadasiv","Kuperan, Ponnudurai","Ong, Kiat Hoe","32129508"],"journal":"Am J Hematol","authors":["Fan, Bingwen Eugene","Chong, Vanessa Cui Lian","Chan, Stephrene Seok Wei","Lim, Gek Hsiang","Lim, Kian Guan Eric","Tan, Guat Bee","Mucheli, Sharavan Sadasiv","Kuperan, Ponnudurai","Ong, Kiat Hoe"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129508","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ajh.25774","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1664640874996301824,"score":98.30288},{"pmid":32311826,"title":"COVID-19 and the clinical hematology laboratory.","text":["COVID-19 and the clinical hematology laboratory.","The ongoing COVID-19 pandemic originated in Wuhan, Hubei Province, China in December 2019. The etiologic agent is a novel coronavirus of presumed zoonotic origin with structural similarity to the viruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Like SARS and MERS, COVID-19 infection manifests most frequently with lower respiratory symptoms. A minority of patients progress to acute respiratory distress syndrome/ diffuse alveolar damage. In addition to its central role in the diagnosis of COVID-19 infection, the clinical laboratory provides critical information to clinicians regarding prognosis, disease course, and response to therapy. The purpose of this review is to 1) provide background context about the origins and course of the pandemic 2) discuss the laboratory's role in the diagnosis of COVID-19 infection 3) summarize the current state of biomarker analysis in COVID-19 infection, with an emphasis on markers derived from the hematology laboratory 4) comment on the impact of COVID-19 on hematology laboratory safety, and 5) describe the impact the pandemic has had on organized national and international educational activities worldwide.","Int J Lab Hematol","Frater, John L","Zini, Gina","d'Onofrio, Giuseppe","Rogers, Heesun J","32311826"],"abstract":["The ongoing COVID-19 pandemic originated in Wuhan, Hubei Province, China in December 2019. The etiologic agent is a novel coronavirus of presumed zoonotic origin with structural similarity to the viruses responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Like SARS and MERS, COVID-19 infection manifests most frequently with lower respiratory symptoms. A minority of patients progress to acute respiratory distress syndrome/ diffuse alveolar damage. In addition to its central role in the diagnosis of COVID-19 infection, the clinical laboratory provides critical information to clinicians regarding prognosis, disease course, and response to therapy. The purpose of this review is to 1) provide background context about the origins and course of the pandemic 2) discuss the laboratory's role in the diagnosis of COVID-19 infection 3) summarize the current state of biomarker analysis in COVID-19 infection, with an emphasis on markers derived from the hematology laboratory 4) comment on the impact of COVID-19 on hematology laboratory safety, and 5) describe the impact the pandemic has had on organized national and international educational activities worldwide."],"journal":"Int J Lab Hematol","authors":["Frater, John L","Zini, Gina","d'Onofrio, Giuseppe","Rogers, Heesun J"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311826","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ijlh.13229","source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501390278658,"score":50.52397},{"pmid":32282949,"title":"Hematological findings and complications of COVID-19.","text":["Hematological findings and complications of COVID-19.","COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening Disseminated intravascular coagulation (DIC) which necessitates continuous vigilance and prompt intervention. COVID-19 infected patients whatever hospitalized or ambulatory are at high risk for VTE and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted.","Am J Hematol","Terpos, Evangelos","Ntanasis-Stathopoulos, Ioannis","Elalamy, Ismail","Kastritis, Efstathios","Sergentanis, Theodoros N","Politou, Marianna","Psaltopoulou, Theodora","Gerotziafas, Grigoris","Dimopoulos, Meletios A","32282949"],"abstract":["COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening Disseminated intravascular coagulation (DIC) which necessitates continuous vigilance and prompt intervention. COVID-19 infected patients whatever hospitalized or ambulatory are at high risk for VTE and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted."],"journal":"Am J Hematol","authors":["Terpos, Evangelos","Ntanasis-Stathopoulos, Ioannis","Elalamy, Ismail","Kastritis, Efstathios","Sergentanis, Theodoros N","Politou, Marianna","Psaltopoulou, Theodora","Gerotziafas, Grigoris","Dimopoulos, Meletios A"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282949","week":"202016|Apr 13 - Apr 19","doi":"10.1002/ajh.25829","source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Lymphopenia"],"e_drugs":["Heparin, Low-Molecular-Weight"],"_version_":1664636704086032385,"score":50.52397},{"pmid":32333199,"title":"Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.","text":["Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.","Pathol Oncol Res","Tsiambas, Evangelos","Papanikolaou, Vasileios","Chrysovergis, Aristeidis","Mastronikolis, Nicholas","Ragos, Vasileios","Kavantzas, Nikolaos","Lazaris, Andreas C","Kyrodimos, Efthymios","32333199"],"journal":"Pathol Oncol Res","authors":["Tsiambas, Evangelos","Papanikolaou, Vasileios","Chrysovergis, Aristeidis","Mastronikolis, Nicholas","Ragos, Vasileios","Kavantzas, Nikolaos","Lazaris, Andreas C","Kyrodimos, Efthymios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333199","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s12253-020-00810-6","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049646014465,"score":46.39981},{"pmid":32204750,"title":"[Standardized management guideline for pediatric wards of hematology and oncology during the epidemic of coronavirus disease 2019].","text":["[Standardized management guideline for pediatric wards of hematology and oncology during the epidemic of coronavirus disease 2019].","With the spread of coronavirus disease 2019 (COVID-19) and growing knowledge of its diagnosis and treatment, it has been clear that children are also susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The children with hematological tumors are a special population with immunosuppression and special therapeutic characteristics. Here the management guideline for pediatric wards of hematology and oncology during COVID-19 epidemic is established based on the features of children with hematological tumors.","Zhongguo Dang Dai Er Ke Za Zhi","32204750"],"abstract":["With the spread of coronavirus disease 2019 (COVID-19) and growing knowledge of its diagnosis and treatment, it has been clear that children are also susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The children with hematological tumors are a special population with immunosuppression and special therapeutic characteristics. Here the management guideline for pediatric wards of hematology and oncology during COVID-19 epidemic is established based on the features of children with hematological tumors."],"journal":"Zhongguo Dang Dai Er Ke Za Zhi","date":"2020-03-25T11:00:00Z","year":2020,"_id":"32204750","week":"202013|Mar 23 - Mar 29","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1663352133684035584,"score":46.11828}]}